This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dybul, M.
Right arrow Articles by Fauci, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dybul, M.
Right arrow Articles by Fauci, A. S.

 Previous Article  |  Next Article 

Journal of Virology, March 2003, p. 3229-3237, Vol. 77, No. 5
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.5.3229-3237.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy

Mark Dybul,1* Marybeth Daucher,1 Mark A. Jensen,2 Claire W. Hallahan,1 Tae-Wook Chun,1 Michael Belson,1 Bertha Hidalgo,1 David C. Nickle,2 Christian Yoder,1 Julia A. Metcalf,1 Richard T. Davey,1 Linda Ehler,1 Diane Kress-Rock,1 Elizabeth Nies-Kraske,1 Shuying Liu,1 James I. Mullins,2 and Anthony S. Fauci1

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,1 Department of Microbiology, University of Washington, Seattle, Washington 981952

Received 5 July 2002/ Accepted 5 December 2002

Various strategies of interrupting highly active antiretroviral therapy (HAART) are being investigated for the treatment of human immunodeficiency virus (HIV) infection. Interruptions of greater than 2 weeks frequently result in rebound of plasma HIV RNA. In order to discern changes in the viral population that might occur during cycles of treatment interruption, we evaluated the homology of HIV-1 envelope gene sequences over time in 12 patients who received four to seven cycles of 4 weeks off HAART followed by 8 weeks on HAART by using the heteroduplex tracking assay and novel statistical tools. HIV populations in 9 of 12 patients diverged from those found in the first cycle in at least one subsequent cycle. The substantial genetic changes noted in HIV env did not correlate with increased or decreased log changes in levels of plasma HIV RNA (P > 0.5). Thus, genetic changes in HIV env itself did not contribute in a systematic way to changes in levels of plasma viremia from cycle to cycle of treatment interruption. In addition, the data suggest that there may be multiple compartments contributing to the rebound of plasma viremia and to viral diversity from cycle to cycle of intermittent therapy.

* Corresponding author. Mailing address: National Institute of Allergy and Infectious Diseases, Bldg. 31/Rm. 7A-03, Bethesda, MD 20892. Phone: (301) 496-2263. Fax: (301) 402-4409. E-mail: mdybul{at}nih.gov.

Journal of Virology, March 2003, p. 3229-3237, Vol. 77, No. 5
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.5.3229-3237.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jensen, M. A., Coetzer, M., van 't Wout, A. B., Morris, L., Mullins, J. I. (2006). A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope v3 sequences.. J. Virol. 80: 4698-4704 [Abstract] [Full Text]  
  • Mondal, D., Williams, C. A., Ali, M., Eilers, M., Agrawal, K. C. (2005). The HIV-1 Tat Protein Selectively Enhances CXCR4 and Inhibits CCR5 Expression in Megakaryocytic K562 Cells. Exp. Biol. Med. 230: 631-644 [Abstract] [Full Text]  
  • Tobin, N. H., Learn, G. H., Holte, S. E., Wang, Y., Melvin, A. J., McKernan, J. L., Pawluk, D. M., Mohan, K. M., Lewis, P. F., Mullins, J. I., Frenkel, L. M. (2005). Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus. J. Virol. 79: 9625-9634 [Abstract] [Full Text]  
  • Monie, D., Simmons, R. P., Nettles, R. E., Kieffer, T. L., Zhou, Y., Zhang, H., Karmon, S., Ingersoll, R., Chadwick, K., Zhang, H., Margolick, J. B., Quinn, T. C., Ray, S. C., Wind-Rotolo, M., Miller, M., Persaud, D., Siliciano, R. F. (2005). A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients. J. Virol. 79: 5185-5202 [Abstract] [Full Text]  
  • Charpentier, C., Dwyer, D. E., Mammano, F., Lecossier, D., Clavel, F., Hance, A. J. (2004). Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors. J. Virol. 78: 4234-4247 [Abstract] [Full Text]  
  • Persaud, D., Siberry, G. K., Ahonkhai, A., Kajdas, J., Monie, D., Hutton, N., Watson, D. C., Quinn, T. C., Ray, S. C., Siliciano, R. F. (2004). Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads. J. Virol. 78: 968-979 [Abstract] [Full Text]  
  • Baccam, P., Thompson, R. J., Li, Y., Sparks, W. O., Belshan, M., Dorman, K. S., Wannemuehler, Y., Oaks, J. L., Cornette, J. L., Carpenter, S. (2003). Subpopulations of Equine Infectious Anemia Virus Rev Coexist In Vivo and Differ in Phenotype. J. Virol. 77: 12122-12131 [Abstract] [Full Text]  
  • Crowe, S., Zhu, T., Muller, W. A. (2003). The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J. Leukoc. Biol. 74: 635-641 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»